# Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

> **NCT03493685** · PHASE3 · COMPLETED · sponsor: **Travere Therapeutics, Inc.** · enrollment: 371 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** sparsentan
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT03493685
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2023-03-20
- **Final completion:** 2026-03-19
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493685, "Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03493685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*